Trinity Biotech (NASDAQ:TRIB) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Trinity Biotech (NASDAQ:TRIB) from a hold rating to a sell rating in a research report released on Thursday.

Trinity Biotech Trading Down 1.1 %

Shares of Trinity Biotech stock opened at $0.68 on Thursday. The business has a 50-day moving average price of $0.84 and a two-hundred day moving average price of $1.25. Trinity Biotech has a 1-year low of $0.63 and a 1-year high of $3.55. The company has a market cap of $12.28 million, a P/E ratio of -0.30 and a beta of 1.03.

Hedge Funds Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its stake in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 378,590 shares of the company’s stock after acquiring an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent reporting period. Institutional investors own 78.97% of the company’s stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.